All In Biotech

Drug Trial Radar · NCT02679755

Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer

A STUDY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE AS TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER FOR WHOM LETROZOLE THERAPY IS DEEMED APPROPRIATE

Last checked: Nov 20, 2026Latest source record: Jul 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

252

Actual

Start

Mar 9, 2016

Primary completion

Jul 25, 2019

Study completion Jul 25, 2019

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Feb 10, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study of palbociclib in combination with letrozole as treatment of post-menopausal women with hormone receptor-positive, her2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate.

Conditions

  • Breast Cancer

Interventions

  • PalbociclibDrug

    125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles

  • LetrozoleDrug

    2.5 mg/d tablets orally on a continuous regimen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (All Causalities)Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months
  2. Number of Participants With Treatment-Emergent Adverse Events by Severity (All Causalities)Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months
  3. Number of Participants With Treatment-Emergent Adverse Events (Palbociclib-Related)Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months
  4. Number of Participants With Treatment-Emergent Adverse Events by Severity (Palbociclib-Related)Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months
  5. Number of Participants With Serious Adverse Events (All Causalities and Palbociclib-Related)Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months

Locations

34 sites in 2 countries. Site status is shown where the registry gives one.

  • Benjamin Carl Forster

    North Sydney, New South Wales, Australia

  • Dr. Alexander Maxwell Menzies

    North Sydney, New South Wales, Australia

  • HPS Pharmacies - North Sydney

    North Sydney, New South Wales, Australia

  • Mater Hospital Sydney

    North Sydney, New South Wales, Australia

  • Professor Frances Mary Boyle

    North Sydney, New South Wales, Australia

  • Royal North Shore Hospital - Clinical Trials Pharmacy

    St Leonards, New South Wales, Australia

  • Royal North Shore Hospital, Dept. of Medical Oncology

    St Leonards, New South Wales, Australia

  • Icon Cancer Care Wesley

    Auchenflower, Queensland, Australia

  • River City Pharmacy

    Auchenflower, Queensland, Australia

  • Icon Cancer Care Chermside

    Chermside, Queensland, Australia

  • Icon Cancer Care South Brisbane

    South Brisbane, Queensland, Australia

  • Icon Cancer Care, Corporate Office

    South Brisbane, Queensland, Australia

  • Icon Cancer Care Southport

    Southport, Queensland, Australia

  • Flinders Medical Centre-Pharmacy Department

    Bedford Park, South Australia, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • Peter MacCallum Cancer Centre Pharmacy

    Melbourne, Victoria, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Sunshine Hospital Pharmacy

    St Albans, Victoria, Australia

  • Sunshine Hospital

    St Albans, Victoria, Australia

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • Pharmacy Department

    Murdoch, Western Australia, Australia

  • The Gujarat Cancer & Research Institute, M.P Shah Cancer Hospital

    Ahmedabad, Gujarat, India

  • Manipal Hospital

    Bangalore, Karnataka, India

  • HealthCare Global Enterprises Ltd.

    Bangalore, Karnataka, India

  • Kasturba Hospital

    Manipal, Karnataka, India

  • Tata Memorial Centre, Tata Memorial Hospital

    Mumbai, Maharashtra, India

  • Meditrina Institute Of Medical Sciences

    Nagpur, Maharashtra, India

  • Shatabdi Hospital

    Nashik, Maharashtra, India

  • Deenanath Mangeshkar Hospital and Research Center

    Pune, Maharashtra, India

  • Sahyadri Super Speciality Hospital

    Pune, Maharashtra, India

  • Rajiv Gandhi Cancer Institute And Research Centre

    New Delhi, National Capital Territory of Delhi, India

  • Dr. B.R.A Institute Rotary Cancer Hospital, All India Institue of Medical Sciences

    New Delhi, National Capital Territory of Delhi, India

  • Apollo Speciality Hospital

    Chennai, Tamil Nadu, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.